CN111032047B - 用于生产光学活性化合物的方法 - Google Patents

用于生产光学活性化合物的方法 Download PDF

Info

Publication number
CN111032047B
CN111032047B CN201880050913.0A CN201880050913A CN111032047B CN 111032047 B CN111032047 B CN 111032047B CN 201880050913 A CN201880050913 A CN 201880050913A CN 111032047 B CN111032047 B CN 111032047B
Authority
CN
China
Prior art keywords
group
compound
salt
acid
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880050913.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111032047A (zh
Inventor
平野沙悠梨
武田善行
中本幸治
池内元树
北山理乙
山田雅俊
川上淳一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Day One Biopharmaceuticals Inc
Original Assignee
Duote Therapy 1 Co
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duote Therapy 1 Co, Millennium Pharmaceuticals Inc filed Critical Duote Therapy 1 Co
Priority to CN202311299784.8A priority Critical patent/CN117447464A/zh
Publication of CN111032047A publication Critical patent/CN111032047A/zh
Application granted granted Critical
Publication of CN111032047B publication Critical patent/CN111032047B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201880050913.0A 2017-05-30 2018-05-29 用于生产光学活性化合物的方法 Active CN111032047B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311299784.8A CN117447464A (zh) 2017-05-30 2018-05-29 用于生产光学活性化合物的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-106280 2017-05-30
JP2017106280 2017-05-30
PCT/IB2018/053822 WO2018220533A2 (ja) 2017-05-30 2018-05-29 光学活性化合物の製造法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311299784.8A Division CN117447464A (zh) 2017-05-30 2018-05-29 用于生产光学活性化合物的方法

Publications (2)

Publication Number Publication Date
CN111032047A CN111032047A (zh) 2020-04-17
CN111032047B true CN111032047B (zh) 2023-10-27

Family

ID=64454503

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880050913.0A Active CN111032047B (zh) 2017-05-30 2018-05-29 用于生产光学活性化合物的方法
CN202311299784.8A Pending CN117447464A (zh) 2017-05-30 2018-05-29 用于生产光学活性化合物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311299784.8A Pending CN117447464A (zh) 2017-05-30 2018-05-29 用于生产光学活性化合物的方法

Country Status (12)

Country Link
US (2) US10988469B2 (https=)
EP (2) EP3632441B1 (https=)
JP (2) JP7102233B2 (https=)
KR (1) KR102754527B1 (https=)
CN (2) CN111032047B (https=)
AU (1) AU2018276192B2 (https=)
CA (1) CA3065683A1 (https=)
EA (1) EA039880B1 (https=)
ES (1) ES2986461T3 (https=)
IL (1) IL270983B (https=)
MX (1) MX391164B (https=)
WO (1) WO2018220533A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391164B (es) 2017-05-30 2025-03-21 Dot Therapeutics 1 Inc Metodo para producir compuesto opticamente activo
CN113557227A (zh) * 2019-03-27 2021-10-26 协和医药化工股份有限公司 前列腺素的制造方法
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
CN114685564B (zh) * 2020-12-27 2023-09-22 西北大学 新型亚磷酰胺配体及其合成方法和应用
EP4377296A1 (en) 2021-07-26 2024-06-05 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法
WO2026028053A2 (en) 2024-07-27 2026-02-05 Assia Chemical Industries Ltd. Process for the preparation of tovorafenib
CN119241530B (zh) * 2024-09-20 2026-04-10 武汉九州钰民医药科技有限公司 一种Tovorafenib的药物合成工艺
CN119241529B (zh) * 2024-09-20 2026-04-10 武汉九州钰民医药科技有限公司 一种Tovorafenib的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095395A2 (en) * 2004-04-02 2005-10-13 Tanabe Seiyaku Co., Ltd. Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors
CN101784545A (zh) * 2007-06-29 2010-07-21 苏尼西斯制药有限公司 用作raf激酶抑制剂的嘧啶衍生物
CN104144929A (zh) * 2012-03-14 2014-11-12 默沙东公司 作为不对称相转移催化剂的金鸡纳生物碱双季盐
CN105008325A (zh) * 2013-03-29 2015-10-28 第一三共株式会社 光学活性二胺化合物的制备方法
CN105524111A (zh) * 2016-01-25 2016-04-27 西北农林科技大学 手性亚膦酰胺单齿配体及其合成方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764842B2 (en) * 2001-03-28 2004-07-20 Merck & Co., Inc. Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7754889B2 (en) * 2004-03-29 2010-07-13 Takasago International Corporation Optically active transition metal-diamine compound and process for producing optically active alcohol with the same
EP2167497A2 (en) * 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
CN107880075A (zh) 2012-03-28 2018-04-06 武田药品工业株式会社 铑催化剂和制备胺化合物的方法
WO2015178846A1 (en) * 2014-05-20 2015-11-26 Sp Process Development Ab Process for the preparation of chiral amines from prochiral ketones
JP6638363B2 (ja) 2015-12-11 2020-01-29 株式会社大林組 掘削装置および杭孔の拡径方法
MX391164B (es) 2017-05-30 2025-03-21 Dot Therapeutics 1 Inc Metodo para producir compuesto opticamente activo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095395A2 (en) * 2004-04-02 2005-10-13 Tanabe Seiyaku Co., Ltd. Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors
CN101784545A (zh) * 2007-06-29 2010-07-21 苏尼西斯制药有限公司 用作raf激酶抑制剂的嘧啶衍生物
CN104144929A (zh) * 2012-03-14 2014-11-12 默沙东公司 作为不对称相转移催化剂的金鸡纳生物碱双季盐
CN105008325A (zh) * 2013-03-29 2015-10-28 第一三共株式会社 光学活性二胺化合物的制备方法
CN105524111A (zh) * 2016-01-25 2016-04-27 西北农林科技大学 手性亚膦酰胺单齿配体及其合成方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Application of Monodentate Secondary Phosphine Oxides, a New Class of Chiral Ligands, in Ir(I)-Catalyzed Asymmetric Imine Hydrogenation";xiao binjiang等;《ORGANIC LETTERS》;20030404;第5卷(第9期);参见图2和表2和化合物16 *

Also Published As

Publication number Publication date
EP3632441A2 (en) 2020-04-08
JP7420865B2 (ja) 2024-01-23
MX391164B (es) 2025-03-21
IL270983B (en) 2022-03-01
US20210347769A1 (en) 2021-11-11
KR102754527B1 (ko) 2025-01-14
JP2018203733A (ja) 2018-12-27
EP4406609A3 (en) 2024-10-02
AU2018276192A1 (en) 2020-01-16
AU2018276192B2 (en) 2022-05-19
EP4406609A2 (en) 2024-07-31
US20200317659A1 (en) 2020-10-08
MX2019014256A (es) 2022-03-31
JP7102233B2 (ja) 2022-07-19
KR20200013707A (ko) 2020-02-07
CN117447464A (zh) 2024-01-26
EP3632441A4 (en) 2021-01-13
WO2018220533A3 (ja) 2019-02-28
ES2986461T3 (es) 2024-11-11
CN111032047A (zh) 2020-04-17
EA201992709A1 (ru) 2020-04-23
WO2018220533A2 (ja) 2018-12-06
CA3065683A1 (en) 2018-12-06
EP3632441C0 (en) 2024-07-17
BR112019025355A2 (pt) 2020-06-23
JP2022116043A (ja) 2022-08-09
US10988469B2 (en) 2021-04-27
EA039880B1 (ru) 2022-03-23
US12129249B2 (en) 2024-10-29
EP3632441B1 (en) 2024-07-17
IL270983A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CN111032047B (zh) 用于生产光学活性化合物的方法
US11053188B2 (en) Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides
US20180079741A1 (en) Process for producing heterocyclic compound
HK40114634A (en) Method for producing optically active compound
HK40022701A (en) Method for producing optically active compound
BR112019025355B1 (pt) Métodos para a produção de compostos oticamente ativos, composto e forma oticamente ativa
CN110753689B (zh) 用于生产杂环化合物的方法
HK40022701B (en) Method for producing optically active compound
RU2793738C2 (ru) Способ получения энантиомерно и диастереомерно обогащенных циклобутанаминов и -амидов
CN106414396B (zh) 制备杂环化合物的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200708

Address after: California, USA

Applicant after: Duote therapy-1 Co.

Address before: Massachusetts, USA

Applicant before: MILLENNIUM PHARMACEUTICALS, Inc.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231107

Address after: California, USA

Patentee after: Day One Biopharmaceuticals

Address before: California, USA

Patentee before: Duote therapy-1 Co.